IB Net Payout Yields Model

Invest like me - only at Covestor.com

Aphria: Avoid After Another Ugly Quarter

By -

 

  • Aphria reported horrible FQ3 results for the period ending February.
  • The Canadian cannabis company only generates 35% of revenue from cannabis sales.
  • The stock is far too expensive with a $4.4 billion market valuation and their prime business only generating ~$210 million in run-rate revenues.
  • Looking for a portfolio of ideas like this one? Members of Out Fox The Street get exclusive access to our model portfolio. Learn More »
Heading into the Tilray (TLRY) merger close, Aphria (APHA) reported a horrible quarter. The company further confirmed why overpaying for Canadian cannabis stocks is never warranted. My investment thesis remains negative on Aphria and the new entity despite a nearly 50% dip from the peak in February.


Read the full article on Seeking Alpha. 

Update - May 3

The deal closes with the new Tilray having a $8 billion valuation. The current FY revenue target is only $790 million, but the numbers include $350 million in non-cannabis revenues. The company just isn't the cannabis powerhouse that most think.

  • Tilray (NASDAQ:TLRY) announced the completion of the previously disclosed merger with its Canadian rival Aphria (NASDAQ:APHA).
  • Tilray shares will continue to trade on the Nasdaq Global Select Exchange and will start trading on Toronto Stock Exchange under the ticker symbol “TLRY” on May 5, 2021, the company said in a press release.
  • From today, Aphria shares will cease trading on Nasdaq with the closing of the deal.
  • The combined companies had a market value of ~$8B based on their last closing stock prices and Tilray shares have added ~2.0% in the premarket today.
  • With the merger, Tilray anticipates $81M (C$100M) of annual pre-tax cost synergies within eighteen months, an accelerated timeline from the previous 24-month target announced at the time of the merger announcement in December.
Tilray was a $10 stock back in November before the U.S. elections and the company doesn't benefit from U.S. legislation. The stock has a ton of downside risk here, especially after Aphria bombed the last quarter. 

Finviz Chart

Update - April 28

Do not follow these analysts still focused on the Canadians for U.S. legalization. 

  • Tilray (NASDAQ:TLRY) and Canopy Growth (NASDAQ:CGC) are both buys, according to Bank of America, because of their ability to enter the U.S. market should federal marijuana legalization occur and CBD beverage distribution.
  • BoA analyst Heather Balsky has reinstated coverage of Tilray and Canopy with price targets of, respectively, $23 and C$45.
  • She rates Aurora Cannabis (NYSE:ACB) as neutral and Cronos Group (NASDAQ:CRON) as underperform.
  • Thanks to the recent shareholder approved merger with Aphria (NASDAQ:APHA), Balsky expects "multiple expansion" thanks to the resultant gains in scale, efficiencies, and combined liquidity.
  • She is modeling $30M-$35M of quarterly EBITDA by 2H 2022.
  • Tilray is also helped by its November 2020 acquisition of SweetWater Brewing, giving it footing in the CBD beverage market and potentially THC-infused products.
The stock valuation is close to $8B and the BofA analyst only forecast $30M in EBITDA next year. The new Tilray will trade at over 60x '22 EBITDA estimates. 


Disclosure: No position mentioned. Please review the disclaimer page for more details. 

Comments

Post a Comment

Popular posts from this blog

Aurora Cannabis: Deal Or No Deal

By -
Aurora Cannabis was left out of the major deal making in 2018. The cannabis company updated FQ2 guidance to revenues of $50 to $55 million with a continued focus on pure production growth. The stock is down as the market is becoming less impressed with commodity farming operations due to the prime Oregon example. The stock is below key resistance at $5.40 as medical cannabis patient totals failed to impress. As the end of 2018 came and went,   Aurora Cannabis   ( ACB ) was a notable absentee from the deal making in the cannabis market. Just about all of the other major Canadian cannabis players got large investments or signed up powerful partnerships, but the related stocks didn't generally maintain rallies following the deals. Based on the early legalization data in Canada and Oregon, the best option for Aurora Cannabis might actually be selling production capacity while the Canadian market remains hot. Read the full article on Seeking Alpha.  Disclosure: No
Read more

C3.ai: Out Of Steam (Rating Downgrade)

By -
Image
This idea was discussed in more depth with members of my private investing community, Out Fox The Street.  Learn More »   Update - June 23, 2023 C3.ai has fallen back to earth after the Investor Day meeting. The Deutsche Bank analyst call on the meeting suggests the company still isn't ready to produce actual numbers from the generative AI demand.  C3.ai ( NYSE: AI ) shares  fell more than 8%  on Friday after investment firm Deutsche Bank reiterated its sell rating on the enterprise software company after it held its investor meeting. Analyst Brad Zelnick said the event "left a lot to be desired" as there were  no details on financials, "limited" updates on the company's operations and investors did not really attend the event, despite it being positioned as for them. "While we appreciate the vast opportunity presented by AI, the event did nothing to ease our skepticism on the true differentiation of the company's platform, its traction with custome
Read more

Archer Aviation: Promising Developments

By -
Image
  Update - June 12, 2023 Archer is finally in the midst of a breakout on the positive FAA news.  -The acting administrator of the Federal Aviation Administration, Billy Nolen, is in talks to join Archer Aviation (NYSE:ACHR), per a report from Reuters. -Citing sources familiar with the situation, the report indicates Nolen will depart his current position atop the FAA in the next few weeks and will then look to transition to a role at Archer (ACHR). Archer’s rival Joby Aviation (JOBY) previously appointed former FAA chief Michael Huerta to a position on its board in March. Original article posted on Jan. 19 This idea was discussed in more depth with members of my private investing community, Out Fox The Street.  Learn More »   Archer Aviation Inc. jumped to $3 on the excitement of small insider purchases. The eVTOL manufacturer recently announced several major developments towards FAA certification and production of the Midnight aircraft. Archer Aviation stock is interesting, with a $70
Read more